Advanced search
Publication Cover
Leukemia & Lymphoma Volume 59, 2018 - Issue 10
Submit an article Journal homepage
169
Views
0
CrossRef citations to date
0
Altmetric
Letter to the Editor

Genetic markers of stable molecular remission in chronic myeloid leukemia after targeted therapy discontinuation

Svetlana A. SmirnikhinaLaboratory of Mutagenesis, FSBI “Research Centre for Medical Genetics”, Moscow, Russian Federation; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-1558-3048View further author information
ORCID Icon,
Ekaterina Yu. ChelyshevaScientific and Advisory Department of Chemotherapy of Myeloproliferative disorders, FSFI “National Research Center for Hematology” of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation; ORCID Iconhttp://orcid.org/0000-0001-6423-1789View further author information
ORCID Icon,
Alexander V. LavrovLaboratory of Mutagenesis, FSBI “Research Centre for Medical Genetics”, Moscow, Russian Federation; ;Department of Molecular and Cellular Genetics, The Russian National Research Medical University Named after N.I. Pirogov, Moscow, Russian FederationORCID Iconhttp://orcid.org/0000-0003-4962-6947View further author information
ORCID Icon,
Konstantin S. Kochergin-NikitskyLaboratory of Mutagenesis, FSBI “Research Centre for Medical Genetics”, Moscow, Russian Federation; ORCID Iconhttp://orcid.org/0000-0002-0096-4542View further author information
ORCID Icon,
Ivan V. MozgovoyDepartment of Molecular and Cellular Genetics, The Russian National Research Medical University Named after N.I. Pirogov, Moscow, Russian FederationView further author information
,
Elmira P. AdilgereevaLaboratory of Mutagenesis, FSBI “Research Centre for Medical Genetics”, Moscow, Russian Federation; ORCID Iconhttp://orcid.org/0000-0002-6440-0500View further author information
ORCID Icon,
Oleg A. ShukhovScientific and Advisory Department of Chemotherapy of Myeloproliferative disorders, FSFI “National Research Center for Hematology” of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation; ORCID Iconhttp://orcid.org/0000-0001-5393-0816View further author information
ORCID Icon,
Anna N. PetrovaScientific and Advisory Department of Chemotherapy of Myeloproliferative disorders, FSFI “National Research Center for Hematology” of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation; View further author information
,
Anastasia V. BykovaScientific and Advisory Department of Chemotherapy of Myeloproliferative disorders, FSFI “National Research Center for Hematology” of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation; View further author information
,
Adhamjon O. AbdullaevScientific and Advisory Department of Chemotherapy of Myeloproliferative disorders, FSFI “National Research Center for Hematology” of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation; ORCID Iconhttp://orcid.org/0000-0003-2530-808XView further author information
ORCID Icon,
Anna G. TurkinaScientific and Advisory Department of Chemotherapy of Myeloproliferative disorders, FSFI “National Research Center for Hematology” of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation; ORCID Iconhttp://orcid.org/0000-0001-9947-2371View further author information
ORCID Icon &
Sergey I. KutsevLaboratory of Mutagenesis, FSBI “Research Centre for Medical Genetics”, Moscow, Russian Federation; ;Department of Molecular and Cellular Genetics, The Russian National Research Medical University Named after N.I. Pirogov, Moscow, Russian FederationORCID Iconhttp://orcid.org/0000-0002-3133-8018View further author information
ORCID Icon show all
Pages 2512-2515 | Received 17 Aug 2017, Accepted 21 Jan 2018, Published online: 09 Feb 2018
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days
Click to increase image sizeClick to decrease image sizeFree first page

Acknowledgements

We thank A.V. Misurin from Genotechnologia (Moscow, Russian Federation) for BCR/ABL measurements and laboratory of DNA diagnostics (Research Centre for Medical Genetics, Moscow, Russian Federation) for Sanger sequencing.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article online at https://doi.org/10.1080/10428194.2018.1434880.

Additional information

Funding

This study was supported (in part) by research funding from Ministry of Education and Science of the Russian Federation by agreement 8113 from 28/08/2012 and 8599 from 14/09/2012. The monitoring of the CML patients was supported by the Healthcare Ministry of Russian Federation. SAS received funding of travel, accommodations, or expenses from BioLine and Novartis Farma, AVL received funding of travel from BioLine and Thermo Fisher Scientific Corporation.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,065.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.